// App-Quantinova.ai

2319 : A Phase 3, Randomized, Multicenter, Open-Label Study of Venetoclax or Pomalidomide in Combination with Dexamethasone in Patients with T(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Researchers

Presenter

  • Maria Mateos

Principal Investigators

  • Philippe Moreau

  • Meletios-Athanasios Dimopoulos

  • Wan-Jen Hong

  • Scott Cooper

  • Yao Yu

  • Muhammad Jalaluddin

  • Jeremy A. Ross

  • Sudeep Karve

  • Sheryl Coppola

  • Paulo C. Maciag

  • Orlando F. Bueno

  • Emma Arriola

  • Shaji K. Kumar

Medical Centers

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Department of Hematology, CHU Nantes, Nantes, France

  • National and Kapodistrian University of Athens, Athens, Greece

  • Genentech, Inc., South San Francisico, CA

  • AbbVie Ltd, Maidenhead, United Kingdom

  • AbbVie, Inc., North Chicago, IL

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

Locations

  • Spain

  • France

  • Greece

  • United States

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03539744

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved